cardiovascular effects of opioid withdrawal have long been studied. it was reported that patients with underlying ischemic heart disease and atherosclerotic vessels may be complicated by a sudden physical and emotional stress due to withdrawal syndrome. but some other believes sudden increase in catecholamine level as a sympathetic overflow might effect on heart with and without underlying isch...

S 7 DEVELOPMENT OF POLYLACTIC/GLYCOLIC ACID DELIVERY SYSTEMS FOR USE IN TREATMENT OF NARCOTIC ADDICTION A.D. Schwope, D.L. Wise, J.F. Howes 13 DEVELOPMENT OF INJECTABLE MICROCAPSULES FOR USE IN THE TREATMENT OF NARCOTIC ADDICTION C. Thies 19 LONG-ACTING NARCOTIC ANTAGONIST COMPLEXES A.P. Gray, W.J. Guardina 21 SUSTAINED RELEASE OF NALTREXONE FROM GLYCERIDE IMPLANTS M.F. Sullivan, D.R. Kalkwarf ...

The mu opioid receptor (MOR, OPRM)--the principal receptor involved in narcotic addiction--has been shown to display basal (spontaneous, constitutive) signaling activity. Interaction with other signaling proteins, such as calmodulin, regulates basal MOR activity. Providing a mechanism for long-lasting regulation, basal MOR activity potentially plays a key role in addiction, in combination with ...

[(3)H]Naloxone, a potent opiate antagonist, binds stereospecifically to opiate-receptor sites in rat-brain tissue. The binding is time, temperature, and pH dependent and saturable with respect to [(3)H]naloxone and tissue concentration. The [(3)H]naloxone-receptor complex formation is bimolecular with a dissociation constant of 20 nM. 15 Opiate agonists and antagonists compete for the same rece...

IT HAS BEEN XaEt'ORTED that, when administered alone, the hvo clinically available narcotic antagonists, nalorphine hydrochloride (Nalline) 1-7 and levallorphan tartrate, 8-1~ have respiratory and circulatory effects similar to those of narcotics. When a third potent narcotic antagonist, naloxone hydrochloride, became available for experimental use, it seemed worthwhile to compare the respirato...